查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1884075

神經科藥物市場規模、佔有率、成長及全球產業分析：按類型、應用和地區劃分的洞察與預測（2024-2032）

Neurology Drugs Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 150 Pages | 商品交期: 請詢問到貨日

價格

神經科藥物市場成長因素

由於全球神經系統疾病的增加以及科學進步推動的治療方法變革，全球神經科藥物市場持續擴張。最新研究顯示，在醫療保健支出成長、新藥上市和神經診斷技術創新等因素的推動下，預計到2024年，該市場規模將達到824.7億美元。隨著治療方法的廣泛應用，預計到2025年，該市場規模將增長至872.6億美元，並在生物製藥、基因療法和個人化醫療的快速發展推動下，到2032年將達到1,341.5億美元。

神經系統藥物對於控制阿茲海默症、帕金森氏症、癲癇、多發性硬化症和腦血管疾病等疾病至關重要。由於人口老化和診斷能力的提高，這些疾病的發生率都在上升。對基因研究、數位神經學工具和生物標記開發的投資不斷增加，使得標靶治療方案得以實現。諾華、拜耳、輝瑞和賽諾菲等領先的製藥公司憑藉其廣泛的產品組合、策略性收購和全球市場覆蓋，保持著強大的市場地位。

市場動態

成長驅動因素

市場成長的主要驅動因素是神經系統疾病盛行率的不斷上升。根據世界衛生組織（WHO，2024年）的預測，全球超過三分之一的人口將受到神經系統疾病的影響，將顯著增加全球疾病負擔。公眾意識的提高和診斷手段的改善促進了早期發現，從而推動了對神經系統藥物的需求。隨著已開發國家和新興國家人口老化，對長期神經系統照護的需求預計將顯著增加。

抑制劑

高昂的治療費用仍是市場擴張的主要障礙。神經系統治療需要大量的研發、多階段臨床試驗以及嚴格的監管審批，這推高了研發成本。最終，這推高了藥品價格，給患者和醫療保健系統都帶來了經濟負擔。例如，美國神經病學會報告稱，2021年多發性硬化症的治療費用將達到每年2,378美元，並且逐年增加。治療費用不斷上漲的趨勢持續限制中低收入社區的藥物負擔能力。

趨勢

技術進步正在改變市場。人工智慧輔助診斷、腦機介面 (BCI)、穿戴式裝置、虛擬實境 (VR) 復健系統和先進的神經影像技術等工具正在改善疾病管理。基因療法已成為治療遺傳性疾病的有力手段，而生物製劑和單株抗體因其標靶作用機制和副作用較小而發展迅速。在政府激勵措施和獨家市場權的支持下，對罕見神經系統疾病治療的投資正在增加。

機會

個人化醫療的日益普及帶來了巨大的機會。基於患者的基因資訊、生物標記和疾病機制的客製化治療有望改善療效並最大限度地減少副作用。這種轉變正促使製藥公司投資先進的藥物設計和精準醫療。

挑戰

神經系統疾病的複雜性帶來了巨大的科學挑戰。神經系統疾病通常是多因素的，其特徵是患者反應各異且難以觸及大腦中的標靶。藥物難以穿過血腦屏障、發展中地區醫療基礎設施有限以及罕見疾病患者招募困難等問題阻礙了藥物研發進程。

市場區隔洞察

按適應症

由於阿茲海默症患者病率不斷上升以及支持早期診斷和治療的宣傳活動日益增多，預計該疾病將推動市場成長。目前，美國約有720萬人患有阿茲海默症。

隨著各公司加強對新型療法的研發力度，多發性硬化症市場預計將穩定成長。

依藥物類別

由於使用率高且近期有新產品獲批，膽鹼酯酶抑制劑佔了最大的市場佔有率。 2021年，FDA批准了用於治療阿茲海默症的藥物ADUHELM，進一步鞏固了這個細分市場。

由於新產品的上市和技術創新帶來的改進，NMDA受體拮抗劑市場也不斷擴張。

依給藥途徑

由於患者依從性高且易於長期使用，口服給藥途徑在2024年佔主導地位。

隨著更多生物製劑和標靶療法進入市場，腸外給藥途徑預計將會成長。

按分銷管道

由於處方率高且患者數量龐大，醫院藥局在2024年佔了最大的市場佔有率。

由於便利性和消費者便利性的提高，零售藥局和網路藥局預計將會成長。

區域展望

2024年，北美地區在神經系統藥物市場佔主導地位，市場規模達420.3億美元（市佔率50.96%）。美國在創新、先進療法的早期應用以及高患者診斷率方面均處於領先地位。歐洲是第二大市場，這得益於其完善的醫療基礎設施和較高的健康意識。亞太地區預計將以最快的速度成長，這主要受疾病盛行率上升、醫療投資增加以及中國和印度人口老化等因素的推動。拉丁美洲以及中東和非洲地區在健保報銷體系和公共衛生政策的完善支持下，呈現穩定成長態勢。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：主要發現

  • 主要神經系統疾病盛行率（按主要國家劃分）
  • 主要國家的監管框架
  • 主要國家的報銷情況
  • 主要公司的新產品上市及核准狀況
  • 主要產業趨勢（併購、合作等）等等）

第五章：全球神經系統藥物市場分析、洞察與預測（2019-2032）

  • 依適應症劃分的市場分析、洞察與預測
    • 阿茲海默症
    • 多發性硬化症
    • 癲癇
    • 帕金森氏症
    • 其他
  • 按藥物類別劃分的市場分析、洞察與預測
    • 膽鹼酯酶抑制劑
    • NMDA受體拮抗劑
    • 抗驚厥藥
    • 免疫調節劑
    • 其他
  • 依給藥途徑劃分的市場分析、洞察與預測
    • 口服
    • 腸外給藥
  • 按給藥途徑劃分的市場分析、洞察與預測- 按分銷管道
    • 醫院藥房
    • 零售藥局和藥局
    • 線上藥房
  • 市場分析、洞察與預測 - 按地區
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章：北美神經系統藥物市場分析、洞察與預測，2019-2032

  • 依國家/地區
    • 美國
    • 加拿大

第七章：歐洲神經系統藥物市場分析、洞察與預測，2019-2032

  • 依國家/地區
    • 德國
    • 美國王國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪的納維亞
    • 歐洲其他地區

第八章 亞太地區神經系統藥物市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 東南亞
    • 亞太其他地區

第九章 拉丁美洲神經系統藥物市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區

第十章 中東東非和非洲神經病學藥物市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 南非
    • 海灣合作委員會
    • 中東和非洲其他地區

第十一章 競爭分析

  • 全球市佔率分析（2024）
  • 公司簡介
    • 衛材株式會社
    • 策略
    • 百健公司
    • 拜耳公司
    • 輝瑞公司
    • 強生公司
    • 諾華公司
    • 默克集團
    • 賽諾菲
    • 艾伯維公司
Product Code: FBI113562

Growth Factors of neurology drugs Market

The global neurology drugs market continues to expand as neurological disorders become more prevalent worldwide and scientific advancements reshape therapeutic approaches. According to the latest findings, the market was valued at USD 82.47 billion in 2024, supported by rising healthcare spending, new drug launches, and technological innovations in neurological diagnostics. The market is projected to increase to USD 87.26 billion in 2025 as treatment adoption rises, and reach USD 134.15 billion by 2032, driven by rapid advancements in biologics, gene therapies, and personalized medicine.

Neurology drugs are essential for managing conditions such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, and cerebrovascular disorders, all of which are becoming more widespread due to aging populations and improved diagnosis capabilities. Increasing investments in genetic research, digital neurology tools, and biomarker development are enabling targeted therapeutic solutions. Prominent pharmaceutical companies-Novartis AG, Bayer AG, Pfizer Inc., and Sanofi-maintain strong positions due to extensive product portfolios, strategic acquisitions, and global market presence.

Market Dynamics

Drivers

A major driver of market growth is the increasing prevalence of neurological disorders. According to the WHO (2024), more than 1 in 3 individuals worldwide are affected by neurological conditions, indicating a substantial rise in the global disease burden. Growing awareness campaigns and improved access to diagnostics have enhanced early detection, driving higher demand for neurology medications. As populations in developed and emerging countries continue to age, the need for long-term neurological care is expected to rise significantly.

Restraints

The high cost of treatment remains a significant barrier to market expansion. Neurology drugs require extensive R&D, multi-phase clinical trials, and rigorous regulatory approvals, which increase development costs. This ultimately raises drug prices, placing financial pressure on both patients and healthcare systems. For instance, the American Academy of Neurology reported that multiple sclerosis treatment costs reached USD 2,378 annually in 2021, with expenses rising each year. Such increasing treatment burdens continue to limit affordability in low-income and middle-income regions.

Trends

The market is experiencing a transformative shift due to technological advancements. Tools such as AI-assisted diagnosis, brain-computer interfaces (BCIs), wearables, virtual reality (VR) rehabilitation systems, and advanced neuroimaging technologies are enhancing disease management. Gene therapies are emerging as powerful approaches for genetic disorders, while biologics and monoclonal antibodies are gaining momentum due to their targeted mechanism of action and reduced adverse effects. Investments in therapies for rare neurological diseases are increasing, supported by government incentives and exclusive marketing rights.

Opportunities

Growing adoption of personalized medicine presents significant opportunities. Tailored treatments based on patient genetics, biomarkers, and specific disease mechanisms are expected to improve outcomes and minimize side effects. This shift is driving pharmaceutical companies to invest in advanced drug design and precision-based therapies.

Challenges

The complexity of neurological disorders poses major scientific challenges. Neurological diseases are often multifactorial, with varied patient responses and difficult-to-access brain targets. Difficulties in drug delivery across the blood-brain barrier, limited healthcare infrastructure in developing regions, and challenges in patient recruitment for rare diseases impede drug development timelines.

Segmentation Insights

By Indication

Alzheimer's disease is projected to dominate the market due to rising prevalence and increasing awareness campaigns that support early diagnosis and treatment. The U.S. currently has approximately 7.2 million people living with Alzheimer's.

Multiple sclerosis is expected to grow steadily as companies intensify R&D for novel therapies.

By Drug Class

Cholinesterase inhibitors hold the largest share due to high usage and recent product approvals. The 2021 FDA approval of ADUHELM for Alzheimer's disease has strengthened the segment.

NMDA receptor antagonists are also expanding due to new launches and technology-driven improvements.

By Route of Administration

The oral segment dominated in 2024 due to high patient compliance and ease of long-term use.

The parenteral segment is expected to grow as more biologics and targeted therapies enter the market.

By Distribution Channel

Hospital pharmacies accounted for the largest share in 2024 due to higher prescription rates and greater patient inflow.

Retail and online pharmacies are projected to grow with increased accessibility and consumer convenience.

Regional Outlook

North America dominated the neurology drugs market in 2024, holding 50.96% market share, valued at USD 42.03 billion. The U.S. leads in innovation, early adoption of advanced therapies, and strong patient diagnosis rates. Europe is the second-largest market, supported by robust healthcare infrastructure and high awareness levels. The Asia Pacific region is expected to grow at the fastest pace, fueled by rising disease prevalence, healthcare investments, and growing elderly populations in China and India. Latin America and the Middle East & Africa show steady growth supported by improved reimbursement and public health initiatives.

Segmentation By Indication

  • Alzheimer's Disease
  • Multiple Sclerosis
  • Epilepsy
  • Parkinson's Disease
  • Others

By Drug Class

  • Cholinesterase Inhibitors
  • NMDA Receptor Antagonist
  • Antiepileptic Drugs
  • Immunomodulatory Drugs
  • Others

By Route of Administration

  • Oral
  • Parenteral

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies & Drug Stores
  • Online Pharmacies

By Region

  • North America (By Indication, Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
    • U.S.
    • Canada
  • Europe (By Indication, Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Germany
    • U.K
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Indication, Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Indication, Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Indication, Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
  • Rest of Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Key Neurological Disorders, By Key Countries/Regions
  • 4.2. Regolatory Framework, By Key Countries/Regions
  • 4.3. Reimbursement Scenario, By Key Countries/Regions
  • 4.4. New Product Launches & Approvals, By Key Players
  • 4.5. Key Industry Developments (Merger, Acquisition, Collaboration, etc.)

5. Global Neurology Drugs Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Indication
    • 5.1.1. Alzheimer's Disease
    • 5.1.2. Moltiple Sclerosis
    • 5.1.3. Epilepsy
    • 5.1.4. Parkinson's Disease
    • 5.1.5. Others
  • 5.2. Market Analysis, Insights and Forecast - By Drug Class
    • 5.2.1. Cholinesterase Inhibitors
    • 5.2.2. NMDA Receptor Antagonist
    • 5.2.3. Antiepileptic Drugs
    • 5.2.4. Immunomodolatory Drugs
    • 5.2.5. Others
  • 5.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.3.1. Oral
    • 5.3.2. Parenteral
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital Pharmacies
    • 5.4.2. Retail Pharmacies & Drug Stores
    • 5.4.3. Online Pharmacies
  • 5.5. Market Analysis, Insights and Forecast - By Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Neurology Drugs Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Indication
    • 6.1.1. Alzheimer's Disease
    • 6.1.2. Moltiple Sclerosis
    • 6.1.3. Epilepsy
    • 6.1.4. Parkinson's Disease
    • 6.1.5. Others
  • 6.2. Market Analysis, Insights and Forecast - By Drug Class
    • 6.2.1. Cholinesterase Inhibitors
    • 6.2.2. NMDA Receptor Antagonist
    • 6.2.3. Antiepileptic Drugs
    • 6.2.4. Immunomodolatory Drugs
    • 6.2.5. Others
  • 6.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.3.1. Oral
    • 6.3.2. Parenteral
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Hospital Pharmacies
    • 6.4.2. Retail Pharmacies & Drug Stores
    • 6.4.3. Online Pharmacies
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Neurology Drugs Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Indication
    • 7.1.1. Alzheimer's Disease
    • 7.1.2. Moltiple Sclerosis
    • 7.1.3. Epilepsy
    • 7.1.4. Parkinson's Disease
    • 7.1.5. Others
  • 7.2. Market Analysis, Insights and Forecast - By Drug Class
    • 7.2.1. Cholinesterase Inhibitors
    • 7.2.2. NMDA Receptor Antagonist
    • 7.2.3. Antiepileptic Drugs
    • 7.2.4. Immunomodolatory Drugs
    • 7.2.5. Others
  • 7.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.3.1. Oral
    • 7.3.2. Parenteral
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Hospital Pharmacies
    • 7.4.2. Retail Pharmacies & Drug Stores
    • 7.4.3. Online Pharmacies
  • 7.5. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 7.5.1. Germany
    • 7.5.2. U.K.
    • 7.5.3. France
    • 7.5.4. Italy
    • 7.5.5. Spain
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Neurology Drugs Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Indication
    • 8.1.1. Alzheimer's Disease
    • 8.1.2. Moltiple Sclerosis
    • 8.1.3. Epilepsy
    • 8.1.4. Parkinson's Disease
    • 8.1.5. Others
  • 8.2. Market Analysis, Insights and Forecast - By Drug Class
    • 8.2.1. Cholinesterase Inhibitors
    • 8.2.2. NMDA Receptor Antagonist
    • 8.2.3. Antiepileptic Drugs
    • 8.2.4. Immunomodolatory Drugs
    • 8.2.5. Others
  • 8.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.3.1. Oral
    • 8.3.2. Parenteral
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Hospital Pharmacies
    • 8.4.2. Retail Pharmacies & Drug Stores
    • 8.4.3. Online Pharmacies
  • 8.5. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 8.5.1. China
    • 8.5.2. India
    • 8.5.3. Japan
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Neurology Drugs Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Indication
    • 9.1.1. Alzheimer's Disease
    • 9.1.2. Moltiple Sclerosis
    • 9.1.3. Epilepsy
    • 9.1.4. Parkinson's Disease
    • 9.1.5. Others
  • 9.2. Market Analysis, Insights and Forecast - By Drug Class
    • 9.2.1. Cholinesterase Inhibitors
    • 9.2.2. NMDA Receptor Antagonist
    • 9.2.3. Antiepileptic Drugs
    • 9.2.4. Immunomodolatory Drugs
    • 9.2.5. Others
  • 9.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.3.1. Oral
    • 9.3.2. Parenteral
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Hospital Pharmacies
    • 9.4.2. Retail Pharmacies & Drug Stores
    • 9.4.3. Online Pharmacies
  • 9.5. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Neurology Drugs Market Analysis, Insights and Forecast, 2019-2032

  • 10.1. Market Analysis, Insights and Forecast - By Indication
    • 10.1.1. Alzheimer's Disease
    • 10.1.2. Moltiple Sclerosis
    • 10.1.3. Epilepsy
    • 10.1.4. Parkinson's Disease
    • 10.1.5. Others
  • 10.2. Market Analysis, Insights and Forecast - By Drug Class
    • 10.2.1. Cholinesterase Inhibitors
    • 10.2.2. NMDA Receptor Antagonist
    • 10.2.3. Antiepileptic Drugs
    • 10.2.4. Immunomodolatory Drugs
    • 10.2.5. Others
  • 10.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.3.1. Oral
    • 10.3.2. Parenteral
  • 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Retail Pharmacies & Drug Stores
    • 10.4.3. Online Pharmacies
  • 10.5. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 10.5.1. South Africa
    • 10.5.2. GCC
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2024)
  • 11.2. Company Profiles
    • 11.2.1. Eisai Co., Ltd.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. Financials (Based on Availability)
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. SWOT, etc.
    • 11.2.2. Strategies
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. Financials (Based on Availability)
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. SWOT, etc.
    • 11.2.3. Biogen Inc.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. Financials (Based on Availability)
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. SWOT, etc.
    • 11.2.4. Bayer AG
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. Financials (Based on Availability)
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. SWOT, etc.
    • 11.2.5. Pfizer Inc.
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. Financials (Based on Availability)
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. SWOT, etc.
    • 11.2.6. Johnson & Johnson Services, Inc.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. Financials (Based on Availability)
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. SWOT, etc.
    • 11.2.7. Novartis AG
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. Financials (Based on Availability)
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. SWOT, etc.
    • 11.2.8. Merck KGaA
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. Financials (Based on Availability)
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. SWOT, etc.
    • 11.2.9. Sanofi
      • 11.2.9.1. Overview
      • 11.2.9.2. Products
      • 11.2.9.3. Financials (Based on Availability)
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. SWOT, etc.
    • 11.2.10. AbbVie Inc.
      • 11.2.10.1. Overview
      • 11.2.10.2. Products
      • 11.2.10.3. Financials (Based on Availability)
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. SWOT, etc.

List of Tables

  • Table 1: Global Neurology Drugs Market Revenue (USD billion) Forecast, By Indication, 2019-2032
  • Table 2: Global Neurology Drugs Market Revenue (USD billion) Forecast, By Drug Class, 2019-2032
  • Table 3: Global Neurology Drugs Market Revenue (USD billion) Forecast, By Route of Administration, 2019-2032
  • Table 4: Global Neurology Drugs Market Revenue (USD billion) Forecast, By Distribution Channel, 2019-2032
  • Table 5: Global Neurology Drugs Market Revenue (USD billion) Forecast, by Region, 2019-2032
  • Table 6: North America Neurology Drugs Market Revenue (USD billion) Forecast, By Indication, 2019-2032
  • Table 7: North America Neurology Drugs Market Revenue (USD billion) Forecast, By Drug Class, 2019-2032
  • Table 8: North America Neurology Drugs Market Revenue (USD billion) Forecast, By Route of Administration, 2019-2032
  • Table 9: North America Neurology Drugs Market Revenue (USD billion) Forecast, By Distribution Channel, 2019-2032
  • Table 10: North America Neurology Drugs Market Revenue (USD billion) Forecast, By Country, 2019-2032
  • Table 11: Europe Neurology Drugs Market Revenue (USD billion) Forecast, By Indication, 2019-2032
  • Table 12: Europe Neurology Drugs Market Revenue (USD billion) Forecast, By Drug Class, 2019-2032
  • Table 13: Europe Neurology Drugs Market Revenue (USD billion) Forecast, By Route of Administration, 2019-2032
  • Table 14: Europe Neurology Drugs Market Revenue (USD billion) Forecast, By Distribution Channel, 2019-2032
  • Table 15: Europe Neurology Drugs Market Revenue (USD billion) Forecast, By Country/Sub-Region, 2019-2032
  • Table 16: Asia Pacific Neurology Drugs Market Revenue (USD billion) Forecast, By Indication, 2019-2032
  • Table 17: Asia Pacific Neurology Drugs Market Revenue (USD billion) Forecast, By Drug Class, 2019-2032
  • Table 18: Asia Pacific Neurology Drugs Market Revenue (USD billion) Forecast, By Route of Administration, 2019-2032
  • Table 19: Asia Pacific Neurology Drugs Market Revenue (USD billion) Forecast, By Distribution Channel, 2019-2032
  • Table 20: Asia Pacific Neurology Drugs Market Revenue (USD billion) Forecast, By Country/Sub-Region, 2019-2032
  • Table 21: Latin America Neurology Drugs Market Revenue (USD billion) Forecast, By Indication, 2019-2032
  • Table 22: Latin America Neurology Drugs Market Revenue (USD billion) Forecast, By Drug Class, 2019-2032
  • Table 23: Latin America Neurology Drugs Market Revenue (USD billion) Forecast, By Route of Administration, 2019-2032
  • Table 24: Latin America Neurology Drugs Market Revenue (USD billion) Forecast, By Distribution Channel, 2019-2032
  • Table 25: Latin America Neurology Drugs Market Revenue (USD billion) Forecast, By Country/Sub-Region, 2019-2032
  • Table 26: Middle East & Africa Neurology Drugs Market Revenue (USD billion) Forecast, By Indication, 2019-2032
  • Table 27: Middle East & Africa Neurology Drugs Market Revenue (USD billion) Forecast, By Drug Class, 2019-2032
  • Table 28: Middle East & Africa Neurology Drugs Market Revenue (USD billion) Forecast, By Route of Administration, 2019-2032
  • Table 29: Middle East & Africa Neurology Drugs Market Revenue (USD billion) Forecast, By Distribution Channel, 2019-2032
  • Table 30: Middle East & Africa Neurology Drugs Market Revenue (USD billion) Forecast, By Country/Sub-Region, 2019-2032

List of Figures

  • Figure 1: Global Neurology Drugs Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032
  • Figure 2: Global Neurology Drugs Market Value Share (%), By Indication, 2024 & 2032
  • Figure 3: Global Neurology Drugs Market Value Share (%), By Drug Class, 2024 & 2032
  • Figure 4: Global Neurology Drugs Market Value Share (%), By Route of Administration, 2024 & 2032
  • Figure 5: Global Neurology Drugs Market Value Share (%), By Distribution Channel, 2024 & 2032
  • Figure 6: Global Neurology Drugs Market Value (USD billion), by Region, 2024 & 2032
  • Figure 7: North America Neurology Drugs Market Value (USD billion), By Indication, 2024 & 2032
  • Figure 8: North America Neurology Drugs Market Value Share (%), By Indication, 2024
  • Figure 9: North America Neurology Drugs Market Value (USD billion), By Drug Class, 2024 & 2032
  • Figure 10: North America Neurology Drugs Market Value Share (%), By Drug Class, 2024
  • Figure 11: North America Neurology Drugs Market Value (USD billion), By Route of Administration, 2024 & 2032
  • Figure 12: North America Neurology Drugs Market Value Share (%), By Route of Administration, 2024
  • Figure 13: North America Neurology Drugs Market Value (USD billion), By Distribution Channel, 2024 & 2032
  • Figure 14: North America Neurology Drugs Market Value Share (%), By Distribution Channel, 2024
  • Figure 15: North America Neurology Drugs Market Value (USD billion), By Country, 2024 & 2032
  • Figure 16: North America Neurology Drugs Market Value Share (%), By Country, 2024
  • Figure 17: Europe Neurology Drugs Market Value (USD billion), By Indication, 2024 & 2032
  • Figure 18: Europe Neurology Drugs Market Value Share (%), By Indication, 2024
  • Figure 19: Europe Neurology Drugs Market Value (USD billion), By Drug Class, 2024 & 2032
  • Figure 20: Europe Neurology Drugs Market Value Share (%), By Drug Class, 2024
  • Figure 21: Europe Neurology Drugs Market Value (USD billion), By Route of Administration, 2024 & 2032
  • Figure 22: Europe Neurology Drugs Market Value Share (%), By Route of Administration, 2024
  • Figure 23: Europe Neurology Drugs Market Value (USD billion), By Distribution Channel, 2024 & 2032
  • Figure 24: Europe Neurology Drugs Market Value Share (%), By Distribution Channel, 2024
  • Figure 25: Europe Neurology Drugs Market Value (USD billion), By Country/Sub-Region, 2024 & 2032
  • Figure 26: Europe Neurology Drugs Market Value Share (%), By Country/Sub-Region, 2024
  • Figure 27: Asia Pacific Neurology Drugs Market Value (USD billion), By Indication, 2024 & 2032
  • Figure 28: Asia Pacific Neurology Drugs Market Value Share (%), By Indication, 2024
  • Figure 29: Asia Pacific Neurology Drugs Market Value (USD billion), By Drug Class, 2024 & 2032
  • Figure 30: Asia Pacific Neurology Drugs Market Value Share (%), By Drug Class, 2024
  • Figure 31: Asia Pacific Neurology Drugs Market Value (USD billion), By Route of Administration, 2024 & 2032
  • Figure 32: Asia Pacific Neurology Drugs Market Value Share (%), By Route of Administration, 2024
  • Figure 33: Asia Pacific Neurology Drugs Market Value (USD billion), By Distribution Channel, 2024 & 2032
  • Figure 34: Asia Pacific Neurology Drugs Market Value Share (%), By Distribution Channel, 2024
  • Figure 35: Asia Pacific Neurology Drugs Market Value (USD billion), By Country/Sub-Region, 2024 & 2032
  • Figure 36: Asia Pacific Neurology Drugs Market Value Share (%), By Country/Sub-Region, 2024
  • Figure 37: Latin America Neurology Drugs Market Value (USD billion), By Indication, 2024 & 2032
  • Figure 38: Latin America Neurology Drugs Market Value Share (%), By Indication, 2024
  • Figure 39: Latin America Neurology Drugs Market Value (USD billion), By Drug Class, 2024 & 2032
  • Figure 40: Latin America Neurology Drugs Market Value Share (%), By Drug Class, 2024
  • Figure 41: Latin America Neurology Drugs Market Value (USD billion), By Route of Administration, 2024 & 2032
  • Figure 42: Latin America Neurology Drugs Market Value Share (%), By Route of Administration, 2024
  • Figure 43: Latin America Neurology Drugs Market Value (USD billion), By Distribution Channel, 2024 & 2032
  • Figure 44: Latin America Neurology Drugs Market Value Share (%), By Distribution Channel, 2024
  • Figure 45: Latin America Neurology Drugs Market Value (USD billion), By Country/Sub-Region, 2024 & 2032
  • Figure 46: Latin America Neurology Drugs Market Value Share (%), By Country/Sub-Region, 2024
  • Figure 47: Middle East & Africa Neurology Drugs Market Value (USD billion), By Indication, 2024 & 2032
  • Figure 48: Middle East & Africa Neurology Drugs Market Value Share (%), By Indication, 2024
  • Figure 49: Middle East & Africa Neurology Drugs Market Value (USD billion), By Drug Class, 2024 & 2032
  • Figure 50: Middle East & Africa Neurology Drugs Market Value Share (%), By Drug Class, 2024
  • Figure 51: Middle East & Africa Neurology Drugs Market Value (USD billion), By Route of Administration, 2024 & 2032
  • Figure 52: Middle East & Africa Neurology Drugs Market Value Share (%), By Route of Administration, 2024
  • Figure 53: Middle East & Africa Neurology Drugs Market Value (USD billion), By Distribution Channel, 2024 & 2032
  • Figure 54: Middle East & Africa Neurology Drugs Market Value Share (%), By Distribution Channel, 2024
  • Figure 55: Middle East & Africa Neurology Drugs Market Value (USD billion), By Country/Sub-Region, 2024 & 2032
  • Figure 56: Middle East & Africa Neurology Drugs Market Value Share (%), By Country/Sub-Region, 2024
  • Figure 57: Global Neurology Drugs Market Share (%), By Company, 2024